Evaluation of Bacteriophage and Antibiotic Synergy Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates

Bokyung Kim; Shukho Kim; Yoon-Jung Choi; Minsang Shin; Jungmin Kim

doi:10.4167/jbv.2025.55.2.131

All Issue

2025 Vol.55, Issue 2 Preview Page Next Page

Original Article

Evaluation of Bacteriophage and Antibiotic Synergy Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates

30 June 2025. pp. 131-141

PDF XML

Abstract

The global rise of carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a serious threat to public health due to limited therapeutic options and high mortality rates. Bacteriophage (phage) therapy has emerged as a promising alternative; however, its effectiveness is often compromised by the rapid development of phage resistance. In this study, we investigated the synergistic potential of phage-antibiotic combination therapy against CRKP. Four phages―vB_KpnM_W9-2, vB_KpnM_W10-2, vB_KpnM_W12-3, and vB_KpnP_W17―were isolated and characterized for adsorption rate, replication dynamics, and environmental stability. Among them, vB_KpnP_W17 exhibited the most favorable adsorption kinetics and stability under various stress conditions. Synergistic interactions between phages and five antibiotics (colistin, meropenem, ciprofloxacin, amikacin, and tigecycline) were assessed in vitro using checkerboard assays against two CRKP clinical isolates. Phage-antibiotic combinations, particularly vB_KpnP_W17 with ciprofloxacin, significantly reduced the minimum inhibitory concentrations of the antibiotics and showed strong synergistic effects. In vivo mouse infection models further confirmed the therapeutic benefit, with repeated administration of the combination treatment resulting in a significant improvement in survival. Overall, these findings suggest that phage-antibiotic combinatorial therapy is a potent and viable strategy to combat CRKP infections and mitigate antibiotic resistance.

Keywords

Carbapenem-resistant Klebsiella pneumoniae

Bacteriophage

Phage therapy

Phage-antibiotic synergy

References

Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72-80.

10.1016/j.mib.2019.10.00831733401

Lepore C, Silver L, Theuretzbacher U, Thomas J, Visi D. The small-molecule antibiotics pipeline: 2014-2018. Nat Rev Drug Discov. 2019;18(10):739.

10.1038/d41573-019-00130-831570838

Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59(10):5873-5884.

10.1128/AAC.01019-1526169401PMC4576115

Selvarajan R, Obize C, Sibanda T, Abia ALK, Long H. Evolution and emergence of antibiotic resistance in given ecosystems: possible strategies for addressing the challenge of antibiotic resistance. Antibiotics (Basel). 2022;12(1):28.

10.3390/antibiotics1201002836671228PMC9855083

Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25(2):219-232.

10.1016/j.chom.2019.01.01430763536

Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-114.

10.4161/bact.1.2.1459022334867PMC3278648

Viertel TM, Ritter K, Horz HP. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother. 2014;69(9):2326-2336.

10.1093/jac/dku17324872344

Wang X, Loh B, Gordillo Altamirano F, Yu Y, Hua X, Leptihn S. Colistin-phage combinations decrease antibiotic resistance in Acinetobacter baumannii via changes in envelope architecture. Emerg Microbes Infect. 2021;10(1):2205-2219.

10.1080/22221751.2021.200267134736365PMC8648044

Chaudhry WN, Concepción-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One. 2017;12(1):e0168615.

10.1371/journal.pone.016861528076361PMC5226664

Dickey J, Perrot V. Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PLoS One. 2019;14(1):e0209390.

10.1371/journal.pone.020939030650088PMC6334939

Kumaran D, Taha M, Yi Q, Ramirez-Arcos S, Diallo JS, Carli A, et al. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. 2018;9:127.

10.3389/fmicb.2018.0012729459853PMC5807357

Torres-Barceló C, Arias-Sánchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One. 2014;9(9):e106628.

10.1371/journal.pone.010662825259735PMC4178015

Kim B, Kim SH, Choi YJ, Shin MS, Kim JM. Characterization of newly isolated bacteriophages targeting carbapenem-resistant Klebsiella pneumoniae. J Microbiol. 2024;62(12):1133-1153.

10.1007/s12275-024-00180-739656423

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100. Wayne (PA): CLSI; 2018.

Gu Liu C, Green SI, Min L, Clark JR, Salazar KC, Terwilliger AL, et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. mBio. 2020;11(4):e01462-20.

10.1128/mBio.01462-2032753497PMC7407087

European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST definitive document E.Def 1.2, May 2000: terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect. 2000;6(9):503-508.

Javaudin F, Latour C, Debarbieux L, Lamy-Besnier Q. Intestinal bacteriophage therapy: looking for optimal efficacy. Clin Microbiol Rev. 2021;34(4):e00136-21.

10.1128/CMR.00136-2134668734PMC8528124

Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017;249:100-133.

10.1016/j.cis.2017.05.01428688779

Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649-659.

10.1128/AAC.45.3.649-659.200111181338PMC90351

Information

Publisher :The Korean Society for Microbiology and The Korean Society of Virology
Publisher(Ko) :대한미생물학회‧대한바이러스학회
Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
Volume : 55
No :2
Pages :131-141
Received Date : 2025-04-22
Revised Date : 2025-05-16
Accepted Date : 2025-05-19
DOI :https://doi.org/10.4167/jbv.2025.55.2.131

JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

All Issue